20872-28-0

Basic information

• Product Name: ethyl 2-(4-hydroxyphenoxy)acetate
• Synonyms: ethyl 2-(4-hydroxyphenoxy)acetate
• CAS NO: 20872-28-0
• Molecular Formula: C₁₀H₁₂O₄
• Molecular Weight: 196.19988
• Mol File: 20872-28-0.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-(4-hydroxyphenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-hydroxyphenoxy)acetate(20872-28-0)
• EPA Substance Registry System: ethyl 2-(4-hydroxyphenoxy)acetate(20872-28-0)

Safety Data

• Hazardous Substances Data: 20872-28-0(Hazardous Substances Data)

Usage

General Description

Ethyl 2-(4-hydroxyphenoxy)acetate is an organic compound and ester of acetic acid. It is commonly used as a fragrance ingredient in the formulation of perfumes, cosmetics, and personal care products. This chemical is known for its sweet, floral, and fruity odor, which makes it a popular choice for adding a pleasant scent to various consumer goods. Ethyl 2-(4-hydroxyphenoxy)acetate also has potential applications in the pharmaceutical industry, where it may be used as an intermediate in the synthesis of other compounds. Overall, this chemical plays an important role in enhancing the sensory experience of a wide range of commercial products.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 150-78-7 1,4-dimethoxybezene 
• 105-39-5 chloroacetic acid ethyl ester 
• 123-31-9 hydroquinone 
• 105-36-2 ethyl bromoacetate 
• 64-17-5 ethanol 
• 1878-84-8 (4-hydroxyphenoxy)acetic acid 
• 142717-44-0 Ethyl 2-(4-benzyloxyphenoxy)ethanoate 
• 37067-27-9 hydroquinone sulphate potassium salt 
• 108-95-2 phenol 
• 38559-92-1 2-(4-Benzyloxyphenoxy)ethanoic acid 
• 18598-23-7 ethyl (4-methoxyphenoxy)acetate 
• 150-76-5 4-methoxy-phenol 
• 103-16-2 4-Benzyloxyphenol 

Downstream Products

• 62489-81-0 ethyl 3-chloro-4-hydroxyphenoxyacetate 
• 52662-27-8 N,N-Diethyl-N'-<(4-hydroxy-phenoxy)-acetyl>-ethylendiamin 
• 97315-40-7 [4-(2-Chloro-ethoxy)-phenoxy]-acetic acid ethyl ester 
• 1878-84-8 (4-hydroxyphenoxy)acetic acid 
• 247133-54-6 ethyl 4-(1-tert-butoxycarbonylpiperidin4-yloxy)-phenoxyacetate 
• 865089-41-4 C₂₉H₂₆N₄O₅S 
• 937245-11-9 C₃₅H₃₀N₄O₅S 
• 247133-55-7 4-(1-tert-butoxycarbonylpiperidin-4-yloxy)phenoxyacetic acid 
• 247133-57-9 5-Cyano-2-[4-(1-tert-butoxycarbonylpiperidin-4-yloxy)phenoxymethyl]-benzimidazole-1-acetic Acid 
• 247133-56-8 N-[4-Cyano-2-[4-(1-tert-butoxycarbonylpiperidin-4-yloxy)phenoxyacetamido]-phenyl]glycine tert-Butyl Ester 

Relevant articles and documents

Design and Structural Optimization of Dual FXR/PPARδActivators

Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence. The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) δhave been validated as molecular targets to counter NASH. To achieve robust therapeutic efficacy in this multifactorial pathology, combined peripheral PPAR?-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach. We have designed a minimal dual FXR/PPARδactivator scaffold by rational fusion of pharmacophores derived from selective agonists. Our dual agonist lead compound exhibited weak agonism on FXR and PPARδand was structurally refined to a potent and balanced FXR/PPARδactivator in a computer-aided fashion. The resulting dual FXR/PPARδmodulator comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.

Preparation and medical use for tetrahydroisoquinoline compound and salt of tetrahydroisoquinoline compound

The invention discloses a novel tetrahydroisoquinoline compound as well as a preparation method, a pharmaceutical composition and use thereof and particularly discloses a compound represented by a general formula (I) (shown in the description), a pharmaceutically acceptable salt of the compound, a preparation process of the compound, a pharmaceutical composition containing the compound representedby the general formula (I) and application of the compound and the composition in the treatment of diseases relevant with type 2 diabetes mellitus, hyperlipidemia and fatty liver.

Campestarenes: New building blocks with 5-fold symmetry

Campestarene is a planar, shape-persistent macrocycle with 5-fold symmetry. A range of derivatives bearing peripheral functional groups suitable for generating supramolecular interactions has been designed and synthesised for potential applications in creating 2D quasicrystal molecular assemblies. The new campestarene derivatives bear ester, carboxylic acid, methoxy, bromo, 4-pyridyl, 4-cyanophenyl and 4-phenyl carboxylic acid groups, including further derivatives of the latter two bearing alkyl chains on the phenyl groups to improve solubility. The campestarene derivatives were prepared by reductive condensation of phenol precursors bearing nitro and formyl groups using Na2S2O4. The target functional groups were installed either by pre-cyclisation derivatisation or by synthesis of methoxy-substituted campestarene and subsequent derivatisation. The cyclisation reaction is tolerant of the functional groups introduced. The ten new campestarene derivatives were characterised by NMR spectroscopy and MALDI-TOF MS, although the poor solubility of some examples precluded their detailed characterisation.